Investor Relations

Investor Relations

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Our lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Download Corporate PresentationDOWNLOAD CORPORATE FACTSHEET

Investor Email Alerts

Join our newsletter!

Sign up to receive the latest news from Cardiol Therapeutics Inc.

By subscribing you agree to with our Privacy Policy

View All Blog Posts
Blog A Woman's Decade-Long Battle Living with Chronic Recurrent Pericarditis and the Impact on Her Dream of Starting a Family

Stolina Qirjazi, a 33-year-old woman from Cleveland, Ohio, describes living with chronic recurrent pericarditis for over a decade and the limitations this condition has imposed on her life, “Be positive. Keep going. Everyday there is hope. Never give up. Never, never.”

October 2, 2023
Blog The Invisible Burden: Understanding the Full Impact of Recurrent Pericarditis

Rachel Freeburg, a resilient woman from Salem, Oregon, shares her story of battling the physical, mental, and financial hurdles of recurrent pericarditis for seven years: “I couldn’t even laugh because I was so exhausted; it rips you apart.”

September 6, 2023
Blog An Indomitable Spirit: A Battle Against Recurrent Pericarditis That Defies the Odds

Alexa Ritchie, 25, has spent the better part of a decade in a constant battle against a rare and debilitating illness that would change the course of her life forever: “It became routine that every couple of months I was down for 7  to 10 days.”

May 30, 2023
Blog From Healthy to Heart Condition: A Mother's Account of Her Son's Myocarditis Battle

Nicole Janes, the mother of 14-year-old Cruze Janes, shares their story of the profound impact of his myocarditis diagnosis: “It started on a Sunday and by Friday he needed to be admitted to the hospital for decreased cardiac function.”

May 9, 2023
Blog Finding the Strength to Persevere: A 5-Year Struggle with Chronic Myopericarditis

Five years ago, Newell Rand, aged 23, was diagnosed with chronic myopericarditis after a series of incorrect diagnoses: “The biggest motivation for me is being able to inspire others.”

April 17, 2023
View All Resources
Resource2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Seth S. Martin, Aaron W. Aday, Zaid I. Almarzooq, et al. Circulation. 2024;149:e347–e913

January 24, 2024
ResourceAn Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects

Martinez Naya N, Kelly J, Corna G, et al. Molecules. 2024;29(2):473.

January 18, 2024
ResourceCannabidiol As A Potential Treatment For Heart Failure With Preserved Ejection Fraction

Lozano O et al. Heart Failure Society of America Annual Scientific Meeting 2023: ePoster Viewing Session III.

October 7, 2023
ResourceMolecular and Cellular Mechanisms of Action of Cannabidiol

Martinez Naya N, Kelly J, Corna G, et al. Molecules. 2023;28(16):5980.

September 8, 2023



Drug Candidate Pre-Clinical Phase 1 Phase 2 Phase 3

Recurrent Pericarditis

Learn More >

Acute Myocarditis

Learn More >

Heart Failure

Learn More >


Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart:



(i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial; NCT05180240) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.
Learn more

Cardiol is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
Learn more

Company History

Cardiol was incorporated on January 19, 2017, and on December 20, 2018, the Corporation completed its initial public offering on the Toronto Stock Exchange. As a result, the Common Shares commenced trading on the TSX under the symbol “CRDL”. On August 10, 2021, the Corporation’s Common Shares commenced trading on the Nasdaq Capital Market under the symbol “CRDL”.